

Characteristic	KEYTRUDA®+ plat/pem (n=410)	Placebo + plat/pem (n=206)
Men	62%	53%
Women	38%	47%
Age (median)	65	63.5
Age (range)	34-84	34-84
ECOG PS		
0	45%	39%
1	54%	61%
2	<1%	0%
Geographic region		
East Asia	1%	3%
Non-East Asia	99%	97%
PD-L1 status		
<1%	31%	31%
≥1%	63%	62%
Not evaluable	6%	7%
Brain metastases (treated or untreated) at baseline		
Yes	18%	17%
No	82%	83%
Platinum chemotherapy		
Cisplatin	28%	28%
Carboplatin	72%	72%